NCT00824408 - Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC | Biotech Hunter

Enrollment

143

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

September 30, 2012

Study Completion Date

August 31, 2015

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

pemetrexed

500 mg/m\^2 i.v. on day 1 of 21 day cycle

DRUG

pemetrexed

500 mg/m\^2 i.v. on day 1 of 21 day cycle

DRUG

BI 6727

BI 6727 i.v. on day 1 of a 21 day cycle

Trial Locations (12)

1230.5.00104 Boehringer Ingelheim Investigational Site, Edmonton

1230.5.00114 Boehringer Ingelheim Investigational Site, Kelowna

1230.5.00109 Boehringer Ingelheim Investigational Site, Surrey

1230.5.00107 Boehringer Ingelheim Investigational Site, Vancouver

1230.5.00105 Boehringer Ingelheim Investigational Site, Hamilton

1230.5.00119 Boehringer Ingelheim Investigational Site, Kitchener

1230.5.00116 Boehringer Ingelheim Investigational Site, Oshawa

1230.5.00108 Boehringer Ingelheim Investigational Site, Ottawa

1230.5.00110 Boehringer Ingelheim Investigational Site, Toronto

1230.5.00102 Boehringer Ingelheim Investigational Site, Montreal

1230.5.00106 Boehringer Ingelheim Investigational Site, Montreal

1230.5.00118 Boehringer Ingelheim Investigational Site, Nassau